Lv6
2128 积分 2025-08-29 加入
Engineering Antibody‐Based Therapeutics: Progress and Opportunities
3小时前
已完结
Colloidal Stability Assessment of a Model Antibody Oligonucleotide Conjugate
2天前
已完结
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs
1个月前
已完结
Immunogenicity risk mitigation of therapeutic proteins with translational immunogenicity, analytical characterization, and regulatory insight
1个月前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
1个月前
已完结
Genetic variants underlying precancerous conditions of hepatocellular carcinoma
1个月前
已完结
Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity
1个月前
已完结
First-in-class versus best-in-class: an update for new market dynamics
1个月前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
1个月前
已完结
Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus
1个月前
已完结
皖公网安备34019202002308
